Literature DB >> 2401751

Norfloxacin does not alter warfarin's disposition or anticoagulant effect.

M L Rocci1, P H Vlasses, L M Distlerath, M H Gregg, S C Wheeler, W Zing, T D Bjornsson.   

Abstract

Drug interactions related to inhibition of hepatic drug metabolism have been identified for some fluoroquinolone antibiotics. This study was designed to investigate whether the fluoroquinolone norfloxacin at the usual clinical dosage interacts with the anticoagulant agent warfarin. Ten healthy male subjects were administered a single oral dose of 30 mg warfarin sodium alone or during multiple-dose treatment with norfloxacin, 400 mg bid, in a randomized, crossover fashion. Plasma warfarin concentrations and prothrombin times were measured for 6 days after each of the two warfarin doses. The pharmacokinetic parameters of warfarin were comparable in the absence and presence of norfloxacin, including no significant differences in warfarin's elimination half-life, apparent total clearance, apparent volume of distribution, or peak plasma concentration. Norfloxacin also had no significant effect on the anticoagulant effect of warfarin, as assessed by the area under the prothrombin time versus time curve and the maximum response for prothrombin time. The lack of pharmacokinetic or pharmacodynamic interaction observed in this study suggests that a clinically important interaction of norfloxacin and warfarin is unlikely to occur in patients requiring both drugs.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2401751     DOI: 10.1002/j.1552-4604.1990.tb03634.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  9 in total

Review 1.  Clinically significant interactions with drugs used in the treatment of tuberculosis.

Authors:  W W Yew
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

2.  Drug interactions with clinafloxacin.

Authors:  E J Randinitis; C W Alvey; J R Koup; G Rausch; R Abel; N J Bron; N J Hounslow; A B Vassos; A J Sedman
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

Review 3.  Drug interactions with quinolone antibacterials.

Authors:  J R Brouwers
Journal:  Drug Saf       Date:  1992 Jul-Aug       Impact factor: 5.606

4.  Moexipril does not alter the pharmacokinetics or pharmacodynamics of warfarin.

Authors:  A Van Hecken; R Verbesselt; M Depré; T B Tjandramaga; J Angehrn; W Cawello; P J De Schepper
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 5.  Clinically important drug interactions with anticoagulants. An update.

Authors:  S Harder; P Thürmann
Journal:  Clin Pharmacokinet       Date:  1996-06       Impact factor: 6.447

6.  Genetic and environmental risk factors for oral anticoagulant overdose.

Authors:  C Verstuyft; A Robert; S Morin; M A Loriot; A Flahault; P Beaune; C Funck-Brentano; P Jaillon; L Becquemont
Journal:  Eur J Clin Pharmacol       Date:  2003-02-18       Impact factor: 2.953

7.  Temafloxacin does not potentiate the anticoagulant effect of warfarin in healthy subjects.

Authors:  E Millar; S Coles; P Wyld; W Nimmo
Journal:  Clin Pharmacokinet       Date:  1992       Impact factor: 6.447

Review 8.  Pharmacokinetic drug interactions with antimicrobial agents.

Authors:  J G Gillum; D S Israel; R E Polk
Journal:  Clin Pharmacokinet       Date:  1993-12       Impact factor: 6.447

Review 9.  Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions.

Authors:  F Pea; M Furlanut
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 5.577

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.